VNDA logo

VNDA
Vanda Pharmaceuticals Inc

4,504
Mkt Cap
$438.5M
Volume
1.25M
52W High
$9.60
52W Low
$3.81
PE Ratio
-5.18
VNDA Fundamentals
Price
$7.43
Prev Close
$7.42
Open
$7.45
50D MA
$7.12
Beta
0.68
Avg. Volume
1.43M
EPS (Annual)
-$0.325
P/B
0.94
Rev/Employee
$540,141.30
$83.75
Loading...
Loading...
News
all
press releases
Vanda Pharmaceuticals Q4 Earnings Call Highlights
Vanda Pharmaceuticals (NASDAQ:VNDA) highlighted strong growth for its lead product Fanapt and detailed several late-stage regulatory and clinical milestones during its fourth-quarter and full-year...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of +78.85% and -2.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7h ago
News Placeholder
Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Quarterly Earnings Results, Beats Expectations By $0.99 EPS
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating analysts...
MarketBeat·8h ago
News Placeholder
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire WASHINGTON, Feb. 11...
PR Newswire·8h ago
News Placeholder
Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of +1.91% and +4.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 23.3% in January
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest...
MarketBeat·9d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·14d ago
News Placeholder
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·15d ago
News Placeholder
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of "Moderate Buy" from Analysts
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six ratings firms that are currently covering the firm, MarketBeat.com reports...
MarketBeat·18d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·21d ago
<
1
2
...
>

Latest VNDA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.